HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol.

Abstract
Twelve cases of Trichosporon spp. fungemias occurring in a national cancer institution within 10 years are described. The trend of hematogenous trichosporonosis within the last 10 years is increasing. While no cases occurred in 1988-1991, after 1991, Trichosporon spp. was the most common species among non-Candida spp. fungemias in 1993-1997. The 12 cases of fungemia included 5 that started while the patients were receiving prophylaxis with oral itraconazole, and 2 appeared despite empiric therapy with amphotericin B. Five of the 12 fungemias were catheter associated. Risk factors for fungemia were: central venous catheter, broad-spectrum antibiotics (third-generation cephalosporins plus aminoglycoside); all but 1 had neutropenia and were receiving antineoplastic chemotherapy. All but 2 of the patients died of systemic fungal infection (83.3% mortality). Amphotericin B was administered to all but 1 patient, who was not treated because he died the day after his culture was found to be positive for T. beigelii, before antifungals were administered. All cases infected with T. pullulans were catheter related, and all these patients died. One of the remaining 9 fungemias was caused by T. capitatum (Blastoschizomyces capitatus), and 8 by T. beigelii. Only 2 patients were cured, 1 with a combination therapy with amphotericin B plus fluconazole, and 1 with amphotericin B monotherapy. Several risk factors (neutropenia, acute leukemia, prior therapy or prophylaxis with antifungals and catheter as source of fungemia, breakthrough fungemia) were significantly associated with Trichosporon spp. fungemia, in comparison to 63 C. albicans candidemia occurring in the same period at the same institution. Attributable mortality of hematogenous trichosporonosis was also significantly higher (83.3% vs. 15.8%, P<0.001) than that of hematogenous candidiasis.
AuthorsV Krcmery Jr, F Mateicka, A Kunová, S Spánik, J Gyarfás, Z Sycová, J Trupl
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 7 Issue 1 Pg. 39-43 (Jan 1999) ISSN: 0941-4355 [Print] Germany
PMID9926973 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antifungal Agents
  • Cephalosporins
  • Itraconazole
  • Amphotericin B
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Aminoglycosides
  • Amphotericin B (administration & dosage, therapeutic use)
  • Anti-Bacterial Agents (therapeutic use)
  • Antifungal Agents (administration & dosage, therapeutic use)
  • Candidiasis (etiology)
  • Catheterization, Central Venous (adverse effects, instrumentation)
  • Catheterization, Peripheral (adverse effects, instrumentation)
  • Cause of Death
  • Cephalosporins (therapeutic use)
  • Chemoprevention
  • Female
  • Fungemia (microbiology, prevention & control)
  • Humans
  • Itraconazole (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Mycoses (etiology, prevention & control)
  • Neoplasms (complications, drug therapy)
  • Neutropenia (complications)
  • Opportunistic Infections (etiology, prevention & control)
  • Risk Factors
  • Trichosporon (classification, drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: